Advanced Diabetes Management System

先进的糖尿病管理系统

• 批准号: 6666667
• 负责人: Alan Letzt
• 金额: $ 25.18万
• 依托单位: ADHERENCE TECHNOLOGIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6666667
• 关键词: automated health care system; biomedical equipment development; clinical research; human subject; noninsulin dependent diabetes mellitus; patient care management; patient monitoring device; telecommunications; therapy compliance

DESCRIPTION (provided by applicant): For the 10 million people in the U.S. with Type 2 diabetes, it is essential to follow strict regimens that include diet, weight, exercise, eye care and foot care. The prescribed regimen promotes glycemic control, which is correlated with better health. Many have proposed interventions that are either time/labor intensive and costly (regular phone calls from nurse), or high tech (Internet web sites). The goal of this research is to determine the feasibility of an advanced diabetes management (ADMS) system that is extremely easy for all patients to use and puts the technology in the hands of the healthcare provider - in a very cost-effective manner. The ADMS places automated interactive telephone calls to patients at scheduled times in a friendly, non-robotic voice to encourage the patient, reinforce goals, and collect data. Advanced speech recognition and Internet technology allow the provider to rapidly input regimens, collect real-time data and review exception reports. Our pilot data suggest that the ADMS concept has merit, is easy for older patients to use, and has significant commercial potential - if we make two significant modifications (described in our application). In phase 1, we will modify the pilot ADMS prototype and conduct a 6-month test with 20 patients at the INOVA Diabetes Center. These data will be compared with data from 20 subjects in a control group. We plan to evaluate system acceptance, value of system features, commercial potential, and ease of use. If Phase 1 is successful, Phase 2 will incorporate lessons from Phase 1 and conduct a 12-month RCT with 160 subjects. A major effort will be made in Phases 1 and 2 to achieve ADA recognition and third-party reimbursement to pave the way for ADMS commercialization.

描述（由申请人提供）：对于美国1000万2型糖尿病患者，必须遵循严格的治疗方案，包括饮食，体重，运动，眼睛护理和足部护理。规定的方案促进血糖控制，这与更好的健康相关。许多人提出的干预措施要么是时间/劳动密集型和昂贵的（定期电话护士），或高科技（互联网网站）。这项研究的目标是确定一种先进的糖尿病管理（ADMS）系统的可行性，该系统非常容易为所有患者使用，并以非常具有成本效益的方式将技术交给医疗保健提供者。 ADMS在预定时间以友好、非机器人的声音向患者拨打自动交互式电话，以鼓励患者、强化目标并收集数据。先进的语音识别和互联网技术使供应商能够快速输入方案，收集实时数据和审查异常报告。 我们的试验数据表明，ADMS概念具有优点，易于老年患者使用，并且具有显著的商业潜力-如果我们进行两个重大修改（在我们的申请中描述）。在第一阶段，我们将修改试点ADMS原型，并在INOVA糖尿病中心对20名患者进行为期6个月的测试。将这些数据与对照组20例受试者的数据进行比较。我们计划评估系统的可接受性、系统功能的价值、商业潜力和易用性。如果第1阶段成功，第2阶段将结合第1阶段的经验教训，并对160名受试者进行为期12个月的RCT。在第一阶段和第二阶段将做出重大努力，以实现ADA的认可和第三方报销，为ADMS的商业化铺平道路。